Midostaurin, sold under the brand name Rydapt, is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis
| Product Name: | Midostaurin |
| Synonyms: | CGP 41251MIDOSTAURIN(PKC412);N-((5S,6R,7R,9R)-6-Methoxy-14-oxo-5,6,7,8,9,14,15,16-octahydro-17-oxa-4b,9a,15-triaza-5,9-Methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-7-yl)-N-MethylbenzaMide;PKC-412, CGP-41251;Midostaurin (PKC412);PKC412 (Midostaurin);CGP 41231;N-Benzoylstaurosporine;(Midostaurin) Benzoylstaurosporine |
| CAS: | 120685-11-2 |
| MF: | C35H30N4O4 |
| MW: | 570.646 |
| EINECS: | 999-999-2 |